Angiogenesis as a Target for Breast Cancer Therapy

Journal of Mammary Gland Biology and Neoplasia

Volumn 4, Issue 4, 1999, Pages 415-423

  Rayson, Daniel ^a,b   Vantyghem, Sharon A ^a,b   Chambers, Ann F ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

Angiogenesis; Breast cancer; Metastasis; Prognosis; Targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR;

ANIMAL; BREAST TUMOR; CLINICAL TRIAL; EXPERIMENTAL NEOPLASM; HUMAN; NEOVASCULARIZATION (PATHOLOGY); REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BREAST NEOPLASMS; CLINICAL TRIALS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0033202785     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018774618873     Document Type: Article

References (69)

1. J. M. Pluda (1997). Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies. Semin. Oncol. 24:203-218.
2. S. Brem (1998). Angiogenesis antagonists: Current clinical trials. Angiogenesis 2:9-20.
3. J. Folkman (1989). What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:4-6.
4. B. R. Zetter (1998). Angiogenesis and tumor metastasis. Ann. Rev. Med. 49:407-424.
5. J. Folkman (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1:27-30.
6. J. Folkman (1995). Clinical applications of research on angiogenesis. N. Engl. J. Med. 333:1757-1763.
7. I. J. Fidler and L. M. Ellis (1994). The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185-188.
8. J. Folkman and P. A. D'Amore (1996). Blood vessel formation: What is its molecular basis? Cell 87:1153-1155.
9. E. C. Kohn (1998). Endostatin and angiostatin: The next antiangiogenesis generation. Angiogenesis 2:25-27.
10. B. P. Eliceiri and D.A. Cheresh (1999). The role of αv integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J. Clin. Invest. 103: 1227-1230.
11. W. G. Stetler-Stevenson (1999). Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. J. Clin. Invest. 103:1237-1241.
12. Y. Veikkola and K. Alitalo (1999). VEGFs, receptors and angiogenesis. Semin. Cancer Biol. 9:211-220.
13. J. Bischoff (1995). Approaches to studying cell adhesion molecules in angiogenesis. Trends Cell Biol. 5:69-74.
14. C. H. Blood and B. R. Zetter (1990). Tumor interactions with the vasculature: Angiogenesis and tumor metastasis. Biochim. Biophys. Acta. 1032:89-118.
15. B. Hobson and J. Denekamp (1984). Endothelial proliferation in tumors and normal tissues: Continuous labeling studies. Brit. J. Cancer 49:405-413.
16. R. Cotran, V. Kumar, and T. Collins (eds.), (1999). Robbins Pathologic Basis of Disease, Sixth Edition, Saunders, Philadelphia, Pennsylvania, pp. 260-327. (Neoplasia).
17. L. R. Bernstein and L. A. Liotta (1994). Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis. Curr. Opin. Oncol. 6:106-113.
18. R. Steiner (1992). Angiogenesis - Historical perspective. In R. Steiner, P. B. Weisz, and R. Langer (eds.), Angiogenesis: Key Principles - Science - Technology-Medicine, Birhauser Verlag, Basel Switzerland, pp.1-3.
19. E. Goldmann (1907). Growth of malignant disease in man and lower animals with special reference to vascular system. Proc. Royal Soc. Med. 1:1-14.
20. E. R. Clark, H. T. Kirby-Smith, R. C. Rex, and R. G. Williams (1930). Recent modifications in the method of studying live cells and tissues in transparent chambers inserted in the rabbit's ear. Anat. Record. 47:187.
21. A. G. Ide, N. H. Baker, and S. L. Warren (1939). Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am. J. Roentgenol. 42:891-899.
22. G. H. Algire (1943). Microscopic studies of the early growth of a transplantable melanoma of the mouse using the transparent chamber technique. J. Natl. Cancer Inst. 4:1-12.
23. G. H. Algire and F. Y. Legallais (1947). Growth rate of transplantable tumor in relation to latent period and host vascular reaction. Cancer Res. 7:724.
24. J. Folkman (1995). Tumor angiogenesis. In J. Mendelsohn, P. M. Howley, M. A. Israel, L. A. Liotta (eds.), The Molecular Basis of Cancer, Saunders, Philadelphia, Pennsylvania, pp 206-232.
25. J. Folkman (1971). Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285:1182-1186.
26. J. Folkman (1996). Fighting cancer by attacking its blood supply. Sci. Am. 275:150-154.
27. J. Folkman, K. Watson, D. Ingber, and D. Hanahan (1989). Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61.
28. M. A. Gimbrone, S. B. Leapman, R. S. Cotran, and J. Folkman (1972). Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136:261-276.
29. J. Folkman (1995). Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med. 333:1757-1763.
30. N. Weidner, J. Folkman, F. Pozza, P. Bevilacqua, E. N. Allred, D. H. Moore, S. Meli, and G. Gasparini (1992). Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 84: 1875-1887.
31. P. J. Polverini and S. J. Leibovich. (1984). Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab. Invest. 51:635-642.
32. J. Folkman (1976) Tumor angiogenesis factor. Cancer Res. 34:2109-2113.
33. L. Holmgren, M. S. O'Reilly, and J. Folkman (1995). Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression Nature Med. 1:149-153.
34. J. Folkman (1985). Tumor angiogenesis. Adv. Cancer Res. 43:175-203.
35. M. S. Pepper, S. J. Mandriota, J-D Vassalli, L. Orci, and R. Montesano (1996). Angiogenesis - Regulating cytokines: Activities and interactions. In U. Günther, P. M. Schlag, and W. Birchmeir (eds.), Attempts to Understand Metastasis Formation II, Springer-Verlag, Berlin, pp. 31-55.
36. H. F. Dvorak, L. F. Brown, M. Detmar, and A. M. Dvorak (1995). Vascular permeability factor/vascular endothelial growth factor, micro vascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146: 1029-1039.
37. J. Folkman and Y. Shing (1992). Angiogenesis. J. Biol. Chem. 267:10931-10934.
38. L. A. Liotta, P. S. Steeg, and W. G. Stetler-Stevenson (1991). Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64:327-336.
39. H. Malonne, I. Langer, R. Kiss, and G. Atassi (1999). Mechanisms of tumor angiogenesis and therapeutic implications: Angiogenesis inhibitors. Clin. Exp. Metastasis 17:1-14.
40. J. Folkman and M. Klagsburn (1987). Angiogenic factor. Science 235:442-447.
41. S. Wylie, I. C. MacDonald, H. J. Varghese, E. E. Schmidt, V. L. Morris, A. C. Groom, and A. F. Chambers (1999). The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Clin. Exp. Metastasis 17:111-117.
42. K. J. Luzzi, H. J. Varghese, I. C. MacDonald, E. E. Schmidt, E. C. Kohn, V. L. Morris, K. E. Marshall, A. F. Chambers, and A. C. Groom (1999). Inhibition of angiogenesis in liver metastases by carboxyamidotriazole (CAI). Angiogenesis 2:373-379.
43. A. F. Chambers, I. C. MacDonald, E. E. Schmidt, V. L. Morris and A. C. Groom (1999). Preclinical assessment of anti-cancer therapeutic strategies using in vivo videomicroscopy. Cancer Metastasis Rev. 17:263-269.
44. M. F. Goldsmith (1999). Leading sites of new cancer cases and deaths - 1999 estimates. JAMA 281:405.
45. C. L. Vogel and J. M. Nabholtz (1999). Monotherapy of metastatic breast cancer: A review of newer agents. The Oncologist 4:17-33.
46. M. J. Ellis (1998). Selective aromatase inhibitors: Current indication and future perspectives. In J. R. Harris and M. E. Lippman (eds.), Diseases of the Breast Updates, Lippincott-Raven, Philadelphia, pp. 1-11.
47. M. M. Goldenberg (1999). Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody. A novel agent for the treatment of metastatic breast cancer. Clin. Therapy 21: 309-318.
48. J. J. Body, R. Bartl, P. Burkhardt, P. D. Delmas, I. J. Diel, H. Fleisch, J. A. Kanis, R. A. Kyle, G. R. Mundy, A. H. G. Paterson, and R. D. Rubens for the International Bone and Cancer Study Group (1998). Current use of bisphosphonates in oncology. J. Clin. Oncol. 16:3890-3899.
49. S. F. Honig (1996). Treatment of metastatic disease. In J. R. Harris, M. E. Lippman, M. Morrow, and S. Hellman (eds.), Diseases of the Breast. Lippincott-Raven, Philadelphia, pp. 669-734.
50. M. J. Piccart, A. Awada, and A. Hamilton (1999). Integration of new therapies into management of metastatic breast cancer: A focus on chemotherapy, treatment selection through use of molecular markers and newly developed biologic therapies in late clinical development. Am. Soc. Clin. Oncol. Ed., 35th Ann. Meeting, pp. 526-539.
51. Early Breast Cancer Trialists' Collaborative Group (1998). Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352:930-942.
52. Early Breast Cancer Trialists' Collaborative Group (1998). Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351: 1451-1467.
53. Program/Proceedings American Society Clinical Oncology (1999). Abstracts 1-4, pp. 1a-2a.
54. Editorial. (1999). Chaos surrounds high-dose chemotherapy for breast cancer. Lancet 353:1633.
55. N. Weidner, J. P. Semple, W. R. Welch, and J. Folkman (1991). Tumor angiogenesis and metastasis - correlation in invasive breast cancer. N. Engl. J. Med. 324:1-8.
56. G. Gasparini and A. L. Harris (1995). Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J. Clin. Oncol. 13:765-782.
57. N. Locopo, M. Fanelli, and G. Gasparini (1998). Clinical significance of angiogenic factors in breast cancer. Breast Cancer Res. Treat. 52: 159-173.
58. L. Martin, B. Green, C. Renshaw, D. Lowe, P. Rudland, S. J. Leinster, and J. Winstanley (1997). Examining the technique of angiogenesis assessment in invasive breast cancer. Brit. J. Cancer 76:1046-1057.
59. I. Hamaguchi, X. L. Huang, N. Takakura, J. Tada, Y. Yamaguchi, H. Kodema, and T. Suda (1999). In vitro hematopoietic and endothelial cell development from cells expressing TEK receptor in murine aorta-gonad-me sonephros region. Blood 93:1549-1556.
60. R. Heimann, D. Ferguson, S. Gray, and S. Hellman (1998). Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis. Breast Cancer Res. Treat. 52:147-158.
61. R. S. Kerbel (1999). Some recent advances in preclinical aspects of treating cancer by inhibition of tumor angiogenesis. Am. Soc. Clin. Oncol. Ed. pp. 4-7.
62. D. Belotti, V. Vergani, T. Drudis, P. Borsotti, M. R. Pitelli, G. Viale, R. Giavizzi, and G. Tarabdetti. (1996). The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2:1843-1849.
63. Angiogenesis inhibitors in clinical trials. http:// cancertrials.nci.nih.gov/
64. G. Gasparini, S. B. Fox, P. Verderio, E. Bonoldi, P. Berilacqua, P. Boracchi, S. Dante, E. Marubini, and A. L. Harris. (1996). Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin. Cancer Res. 2:1191-1198.
65. A. Makris, T. J. Powles, S. Kakolyris, M. Dowsett, S. E. Ashley, and A. L. Harris. (1999). Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer 85:1996-2000.
66. S. G. Eckhardt and J. M. Pluda. (1997). Development of angiogenesis inhibitors for cancer therapy. Invest. New Drugs 15:1-3.
67. J. N. Ingle, V. J. Suman, C. G. Kardinal, J. E. Krook, J. A. Maillard, M. H. Veeder, C. L. Loprinzi, R. J. Dalton, L. C. Hartmann, C. A. Conaver, and M. N. Pollak (1999). A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 85:1284-1292.
68. T. Boehm, J. Folkman, T. Browder, and M. S. O'Reilly (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407.
69. R. S. Kerbel (1997). A cancer therapy resistant to resistance (News and Views). Nature 390:335-336.